At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

Míreanna comhchosúla

• Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.
  de réir: Paietta, E, et al.
  Foilsithe / Cruthaithe: (2008)
• Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2010)
• Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2010)
• Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2010)
• UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
  de réir: Fielding, A, et al.
  Foilsithe / Cruthaithe: (2014)